Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 626 - 650 of 1990 in total

Quizartinib

Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind. Additionally, quizartinib also demonstrates inhibitory activity toward FLT3 with internal tandem duplication (ITD), although...
Approved
Investigational
Matched Description: … Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug ... thus poorer overall survival and higher risk of relapse. ... anthracycline induction and standard cytarabine consolidation, followed by a maintenance monotherapy …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Eslicarbazepine acetate

Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy. Eslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body....
Approved
Matched Description: … Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and ... Eslicarbazepine acetate is marketed as Aptiom in North America and Zebinix or Exalief in Europe. ... , but it is known that it does exert anticonvulsant activity by inhibiting repeated neuronal firing and …
Matched Categories: … Eslicarbazepine and prodrugs …

Choline C-11

Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging.
Approved
Matched Description: … for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and …

Linzagolix

Linzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis.[A253642,A253647] It is similar to other GnRH receptor antagonists like cetrorelix, relugolix, and elagolix. Uterine fibroids occur in >70% of women of reproductive...
Approved
Matched Description: … , and reproductive dysfunction. ... [A253642,A253647] It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and ... Uterine fibroids occur in >70% of women of reproductive age, and when symptomatic are associated with …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins …

Mavorixafor

Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized by a reduced number of mature neutrophils and lymphocytes. WHIM syndrome is caused by...
Approved
Investigational
Matched Description: … [L50642] As CXCR4 mutations have also been implicated in human immunodeficiency virus (HIV), Waldenstrom ... approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and ... syndrome, a genetic immunodeficiency disorder characterized by a reduced number of mature neutrophils and …

Secukinumab

Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan...
Approved
Matched Description: … Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory ... in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and ... chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Cobicistat

Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized...
Approved
Matched Description: … Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human ... exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and ... activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and …
Matched Categories: … darunavir and cobicistat ... atazanavir and cobicistat ... Metabolic Side Effects of Drugs and Substances ... emtricitabine, tenofovir alafenamide, darunavir and cobicistat ... emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat …

Aminolevulinic acid

A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Approved
Matched Description: … A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …

Aztreonam

A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
Approved
Matched Description: … , bladder, and kidneys. ... It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges …

Prasugrel

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing...
Approved
Matched Description: … and pharmacologically related to clopidogrel and ticlopidine. ... Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada ... As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. …
Matched Categories: … Blood and Blood Forming Organs …

Brexpiprazole

Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to aripiprazole, brexpiprazole has different binding affinities for dopamine and serotonin receptors. Compared...
Approved
Investigational
Matched Description: … Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called ... It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors. ... It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. …

Agomelatine

Agomelatine is structurally closely related to melatonin. Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors, tested in an animal model of depression. Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines Agency (EMA) in 2005. The Committee...
Approved
Investigational
Matched Description: … The Committee for Medical Products for Human Use (CHMP) recommended refusal of marketing authorization ... Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin-2C (5-HT2C) receptors ... Agomelatine was developed in Europe by Servier Laboratories Ltd. and submitted to the European Medicines …

Mupirocin

Mupirocin, formerly termed pseudomonic acid A, is a novel antibacterial agent with a unique chemical structure and mode of action apart from other antibiotic agents. Produced by fermentation using the organism Pseudomonas fluorescens, mupirocin is a naturally-occurring antibiotic that displays a broad-specturm activity against many gram-positive bacteria and certain gram-negative...
Approved
Investigational
Vet approved
Matched Description: … and traumatic skin lesions due to secondary skin infections caused by _S. aureus_ and _S. pyogenes_. ... termed pseudomonic acid A,[A178531] is a novel antibacterial agent with a unique chemical structure and ... is used in the treatment of impetigo caused by _Staphylococcus aureus_ and _Streptococcus pyogenes_ …
Matched Mixtures name: … Pre and Post Sx Pouch …

Dupilumab

Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in several atopic or...
Approved
Investigational
Matched Description: … Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin ... immunological reactions in several atopic or allergic conditions, such as eczema, allergic reaction, and ... dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents …

Hydrocortisone butyrate

Approved
Vet approved
Matched Categories: … Hydrocortisone and derivatives ... hydrocortisone butyrate and antiseptics ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Hydrocortisone cypionate

Approved
Investigational
Vet approved
Matched Categories: … Hydrocortisone and derivatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Hydrocortisone phosphate

Approved
Vet approved
Matched Categories: … Hydrocortisone and derivatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Hydrocortisone probutate

Approved
Vet approved
Matched Categories: … Hydrocortisone and derivatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Hydrocortisone valerate

Approved
Vet approved
Matched Categories: … Hydrocortisone and derivatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Tofersen

Tofersen is under an intrathecally administered antisense oligonucleotide targeting the mutated SOD1 gene that causes amyotrophic lateral sclerosis (ALS). Although there were various causes of ALS, 2% of ALS cases are due to SOD1 mutations, with more than 200 SOD1 mutations documented.[A259028,A259033] Tofersen was granted accelerated approval from the FDA...
Approved
Investigational
Matched Description: … [A259023] However, it could potentially be due to the short timeframe of tofersen treatment, and more ... [L46133] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …

Pembrolizumab

Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes...
Approved
Matched Description: … generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human ... as interchain bonds and 23 interchain bonds. ... [A18829] It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Ceftobiprole medocaril

Ceftobiprole medocaril is a prodrug of ceftobiprole, a fifth-generation semisynthetic cephalosporin antibacterial. Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains of Staphylcoccus aureus (methicillin-resistant Staphylococcus aureus; MRSA). The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion...
Approved
Experimental
Investigational
Matched Description: … The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole ... infections and bacteremia in April 2024. ... Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative …

Eteplirsen

Eteplirsen is a synthetic antisense oligonucleotide and a phosphorodiamidate morpholino oligomer. It consists of a six-membered morpholino ring replacing the five-membered ribofuranosyl rings found in natural DNA and RNA. Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and premature death most commonly due to respiratory...
Approved
Investigational
Matched Description: … Eteplirsen is a synthetic antisense oligonucleotide and a phosphorodiamidate morpholino oligomer. ... a six-membered morpholino ring replacing the five-membered ribofuranosyl rings found in natural DNA and ... Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle deterioration and …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …

Momelotinib

Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. First approved by the FDA on September 15, 2023, momelotinib is used to treat myelofibrosis. Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells,...
Approved
Investigational
Matched Description: … Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. ... Clinical manifestations of MF include anemia and thrombocytosis. ... MF includes primary MF (PMF), post-polycythemia vera (PV) MF, and post-essential thrombocythemia (ET) …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Efanesoctocog alfa

Efanesoctocog alfa (BIVV001) is a recombinant factor VIII (FVIII) analogue fusion protein used for the routine prophylaxis, perioperative management of bleeding and on-demand treatment and control of bleeding episodes in patients with hemophilia A. The use of FVIII replacement products is beneficial in patients with hemophilia A; however, their quality...
Approved
Investigational
Matched Description: … on-demand treatment and control of bleeding episodes in patients with hemophilia A. ... FVIII) analogue fusion protein used for the routine prophylaxis, perioperative management of bleeding and ... [A257464] Efanesoctocog alfa was designed to have an extended half-life, and to surpass the half-life …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Displaying drugs 626 - 650 of 1990 in total